An observational study in Peripheral Arterial Disease, sponsored by Biotronik AG. Completed at 17 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-01.
Sponsored by Biotronik AG (formerly part of Biotronik SE & Co. KG) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG — 1 open to participants now, 2 under way, none of them phase 3. Peripheral Arterial Disease · Biotronik SE & Co. KG.
Among the 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG, this one is the only one that started in 2023, is one of 7 observational ones, and was the 13th registered.
1,377 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →1 of the 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG is open now, in 8 countries. Recruiting first, the newest first:
Biotronik AG · Sites in Austria, Belgium, France and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2023.
This study's enrollment of 380 is above the median of 187 across 399 observational studies indexed under Peripheral Arterial Disease.
Median enrollment 111 across the 8 interventional studies, 200 across the 7 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Biotronik AG, one of the names counted as Biotronik SE & Co. KG. Under that name alone:
Biotronik AG is the lead sponsor of 40 studies on the registry; 2 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Significant advances in dedicated materials and techniques along with increased operator experience led to a significant increment in procedural success rate of peripheral endovascular interventions, exceeding 90% in expert hands with reported low procedural complication rates. However, there are still lack of data on procedural outcomes, in-hospital complications, and resource utilization on treatment of (complex) lesions in the femoral, popliteal and infrapopliteal artery in the real-world condition in Europe.
The study will enroll consecutive eligible subjects who have peripheral artery disease (PAD) requiring endovascular treatment of de-novo and restenotic atherosclerotic lesions in femoral, popliteal and infrapopliteal arteries.
The purpose of this prospective, multicenter, observational European Study is to evaluate the standard of care practices, procedural outcomes, and in-hospital complications of endovascular peripheral interventions for treatment of lesions in the femoral, popliteal and infrapopliteal arteries.
Subjects who have PAD with target lesion(s) located in the femoral, popliteal and/or infrapopliteal artery are eligible for the study. Up to 380 subjects will be enrolled in approximately 12 investigational sites in Europe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Multiple consecutive single lesions with a healthy segment(s) of ≤ 3cm in-between the lesions will be considered one lesion.
For Above the knee (ATK) group
Successful treatment of inflow iliac stenosis to the target lesion. Inflow lesion stenosis can be treated during the same procedure as per local standard of care.
For Below the knee (BTK) group:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau)
Target lesions involve arteries below the tibial plateau
Procedural success rate
Combination of technical success and absence of procedural complications
Time frame: Index Procedure
Procedure technical success rate
successful crossing and achievement of a final residual diameter stenosis of ≤30% of the treated target lesion on the procedural completion angiography
Time frame: Index Procedure
Rate of target lesion bailout stenting
Stented target lesion
Time frame: Index Procedure
Stented length
Stented length
Time frame: Index Procedure
Rate of PTA balloon related flow-limiting dissections
PTA balloon related flow-limiting dissections
Time frame: Index Procedure
Rate of distal embolization
Distal embolization
Time frame: Index Procedure
Rate of target vessel rupture
Target vessel rupture
Time frame: Index Procedure
Rate of target vessel perforation
Target vessel perforation
Time frame: Index Procedure
Rate of acute occlusion
Acute occlusion
Time frame: Index Procedure
Primary crossing success rate
Successfully placement of a guidewire into the distal true lumen with the primary crossing strategy
Time frame: Index Procedure
Rate of Serious Adverse Device Effects
Serious Adverse Device Effects
Time frame: Index Procedure
Non-labor resource use
Devices use
Time frame: Index procedure until discharge
Plan to share: Undecided — The individual participant data (IPD) is not yet drafted. No decision is taken to share it yet.
No publications or documents are linked to this record.
Ran from May 2023 to primary completion in Jun 2024, 12 months.
Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 12 months is below that.
Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.